Aurinia Pharmaceuticals
AUPH
62 hedge funds and large institutions have $147M invested in Aurinia Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 10 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
3% more capital invested
Capital invested by funds: $142M → $147M (+$4.7M)
0.17% less ownership
Funds ownership: 28.23% → 28.06% (-0.17%)
5% less funds holding
Funds holding: 65 → 62 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
61% less call options, than puts
Call options by funds: $2.15M | Put options by funds: $5.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$2.74M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.26M |
| 3 |
KAM
Kazazian Asset Management
Fort Lauderdale,
Florida
|
+$464K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$379K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$328K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.56M |
| 2 |
OFG
OTA Financial Group
Purchase,
New York
|
-$1.29M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$598K |
| 4 |
Bank of New York Mellon
New York
|
-$502K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$387K |
AUPH Hedge Fund Activity: Q3 2017 in Review
62 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2017, worth a combined $147M — up 3.3% from $142M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AUPH and 8 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 23 added.
The largest buyer was Polar Capital, adding an estimated $2.74M. The largest seller was Nicholas Investment Partners, exiting entirely with an estimated $1.56M sold.
- 62 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2017, down from 65 in Q2 2017.
- Funds reported $147M of Aurinia Pharmaceuticals stock for Q3 2017, up 3.3% quarter-over-quarter.
- 8 funds opened new Aurinia Pharmaceuticals positions in Q3 2017 and 10 closed out, a net change of -2 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2017 was Polar Capital, an estimated $2.74M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2017 was Nicholas Investment Partners, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2017.